Results from CheckMate-227 : Immune combination reaches PFS endpoint

Bookmark and Share
Published: 25 Apr 2018
Views: 5508
Dr Matthew Hellmann - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Hellmann presents results at AACR 2018 from CheckMate-227, assessing a combination of nivolumab and ipilimumab in cases of newly diagnosed non-small cell lung cancer with high mutational burden.

The 139 patients treated with the combination were 42% less likely to have their disease to progress compared to those treated with chemotherapy.

Overall survival data are still maturing.